{
 "as_of": "2026-11-06",
 "cmr": "se-cm-kg/SSME/SE0021181559",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Disruptive Pharma AB (First North Sweden: SE0021181559) — research page\n\nAs of 2026-11-06 · se-cm-kg · record version 1\n\n## Identity and listing\n\nDisruptive Pharma AB is listed on First North Sweden under the ticker SE0021181559 and ISIN SE0021181559, with LEI 549300DTX7T87FGYG180. The security type, segment, sector and jurisdiction are not on the record. The issuer is listed and not halted.\n\n## The disclosure read\n\nThe record holds 27 filings across 24 filing days in the twelve months to 2026-11-06. The median gap between filing days is 14 days. The latest filing is dated 2026-11-02, is of type Other information disclosed according to the rules of the Exchange, and is 4 days before the record date. The First North Sweden medians are 11.0 days for cadence and 7 days for latency, across 325 issuers with a median of 21 filings. The sector median is not on the record.\n\n## Auditor\n\nThe auditor and its location are not on the record. The market's record does not carry auditor changes.\n\n## Events and halts\n\nThe record does not carry listing, delisting, name change, domicile change or segment move events for this market. The issuer is listed and not halted.\n\n## Orderability\n\nThe outcome is not determinable because the chapter's orderability section carries no client categories for this issuer. Rule version acm-68000/se/mifid-ii-product-governance/r1 applies, with chapter as of 2026-11-04.\n\n## Coverage\n\nNo research houses were named on the issuer's investor-relations pages read, and the count is 0.\n\n## Open research\n\nOne openly published research note is on the record, from Edison Investment Research dated 2026-09-08.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe market's vintage is not sealed. No issuer years are sealed, and the earliest sealed date for the market and the date the live record began are not on the record.\n\n## Sources\n\n7 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://firds.esma.europa.eu/firds/ (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.se-cm-kg.ai/events/SSME/SE0021181559 (the disclosure lines)\n- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)\n- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://www.edisongroup.com/research/reverse-takeover-resets-the-investment-case/BM-3884 (open research)\n- https://mcp.se-cm-kg.ai/record/SSME/SE0021181559 (the record)\n",
 "market": "SE",
 "node": "se-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": null,
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "the SE vintage is not sealed; the record is the live record as of 2026-11-06",
   "record_version": 1,
   "sealed": false
  },
  "auditor": {
   "auditor": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "SE",
    "state": "not_on_record"
   },
   "changes": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "cmr": "se-cm-kg/SSME/SE0021181559",
  "coverage": {
   "count": 0,
   "houses": [],
   "pages_checked": [
    {
     "page": "https://disruptivepharma.com/investors/",
     "result": "read: 0 of 0 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": null,
   "state": "none_found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 325,
     "median_cadence_gap_days": 11,
     "median_filings": 21,
     "median_latency_days": 7,
     "name": "First North Sweden"
    },
    "sector": {
     "market": "SE",
     "state": "not_on_record"
    }
   },
   "by_type": {
    "Annual financial report": 1,
    "Changes in board/management/certified adviser/auditor/liquidity provider": 1,
    "Company Announcement": 1,
    "Company description / prospectus": 1,
    "Corporate Action": 1,
    "Decisions of general meeting": 2,
    "Financial statement release": 1,
    "Half year financial report": 1,
    "Interim report (Q1 and Q3)": 2,
    "Investor News": 9,
    "Notice to general meeting": 2,
    "Other information disclosed according to the rules of the Exchange": 5
   },
   "cadence_median_gap_days": 14,
   "filing_days": 24,
   "filings": 27,
   "latency_days": 4,
   "latest": [
    {
     "category": "Other information disclosed according to the rules of the Exchange",
     "date": "2026-11-02",
     "source": "https://view.news.eu.nasdaq.com/view?id=b5d6a15c4abecd2a305c8058ae1a585b1&lang=sv&src=listed",
     "title": "Disruptive Pharma presenterar valberedningen för 2027",
     "type": "Other information disclosed according to the rules of the Exchange"
    },
    {
     "category": "Investor News",
     "date": "2026-09-22",
     "source": "https://view.news.eu.nasdaq.com/view?id=b93a9f7de4f16e141babb99598312b934&lang=en&src=listed",
     "title": "Disruptive Pharma divests GTX platform and retains rights to future royalty and milestone revenues",
     "type": "Investor News"
    },
    {
     "category": "Half year financial report",
     "date": "2026-08-20",
     "source": "https://view.news.eu.nasdaq.com/view?id=baaccd3fbc87f8295c3bf4a22f5ceca4a&lang=sv&src=listed",
     "title": "Disruptive Pharma offentliggör delårsrapport för januari-juni 2026",
     "type": "Half year financial report"
    },
    {
     "category": "Investor News",
     "date": "2026-08-18",
     "source": "https://view.news.eu.nasdaq.com/view?id=b28dfe4530f9ba8878cdb9017db2afdf5&lang=en&src=listed",
     "title": "Disruptive Pharma to ring the opening bell at Nasdaq Stockholm",
     "type": "Investor News"
    },
    {
     "category": "Other information disclosed according to the rules of the Exchange",
     "date": "2026-07-27",
     "source": "https://view.news.eu.nasdaq.com/view?id=ba20f95fa9c9fbc957c8c25d817bed35c&lang=en&src=listed",
     "title": "Guard Therapeutics Completes Reverse Takeover of Disruptive Pharma and Executes In-Kind Share Issue",
     "type": "Other information disclosed according to the rules of the Exchange"
    }
   ],
   "latest_filing_date": "2026-11-02",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.se-cm-kg.ai/events/SSME/SE0021181559",
   "window": {
    "from": "2025-11-06",
    "to": "2026-11-06"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "First North Sweden"
   },
   "isin": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0021181559"
   },
   "jurisdiction": {
    "market": "SE",
    "state": "not_on_record"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-09",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN SE0021181559)",
    "state": "sourced",
    "value": "549300DTX7T87FGYG180"
   },
   "name": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Disruptive Pharma AB"
   },
   "sector": {
    "market": "SE",
    "state": "not_on_record"
   },
   "security_type": {
    "market": "SE",
    "state": "not_on_record"
   },
   "segment": {
    "market": "SE",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0021181559"
   },
   "website": {
    "market": "SE",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "domicile_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "listing": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "name_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "segment_move": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "market": "SE",
  "node": "se-cm-kg",
  "numbers_hash": "sha256:35b7353ed6eccd4982f6b6192dbd3d4826076c80b96ead5885dd0de98b118578",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [
    {
     "date": "2026-09-08",
     "kind": "issuer-sponsored",
     "publisher": "Edison Investment Research",
     "read_by": "the note's own page, fetched by this rail",
     "read_date": "2026-11-12",
     "source": "https://www.edisongroup.com/research/reverse-takeover-resets-the-investment-case/BM-3884",
     "state": "sourced",
     "title": "Disruptive Pharma — Reverse takeover resets the investment case"
    }
   ],
   "state": "found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://se.eu-cm-kg.ai/book/aio.json",
    "door": "https://se.eu-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/se/mifid-ii-product-governance/r1",
   "section": "se.aio.v5"
  },
  "record": {
   "as_of": "2026-11-06",
   "url": "https://mcp.se-cm-kg.ai/record/SSME/SE0021181559",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-09",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:35b7353ed6eccd4982f6b6192dbd3d4826076c80b96ead5885dd0de98b118578",
 "path": "/se/SSME/SE0021181559",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "Disruptive Pharma AB is listed on First North Sweden under the ticker SE0021181559 and ISIN SE0021181559, with LEI 549300DTX7T87FGYG180. The security type, segment, sector and jurisdiction are not on the record. The issuer is listed and not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 27 filings across 24 filing days in the twelve months to 2026-11-06. The median gap between filing days is 14 days. The latest filing is dated 2026-11-02, is of type Other information disclosed according to the rules of the Exchange, and is 4 days before the record date. The First North Sweden medians are 11.0 days for cadence and 7 days for latency, across 325 issuers with a median of 21 filings. The sector median is not on the record.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor and its location are not on the record. The market's record does not carry auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record does not carry listing, delisting, name change, domicile change or segment move events for this market. The issuer is listed and not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable because the chapter's orderability section carries no client categories for this issuer. Rule version acm-68000/se/mifid-ii-product-governance/r1 applies, with chapter as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "No research houses were named on the issuer's investor-relations pages read, and the count is 0.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "One openly published research note is on the record, from Edison Investment Research dated 2026-09-08.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The market's vintage is not sealed. No issuer years are sealed, and the earliest sealed date for the market and the date the live record began are not on the record.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "7 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://firds.esma.europa.eu/firds/"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.se-cm-kg.ai/events/SSME/SE0021181559"
  },
  {
   "for": "the halt flag",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation"
  },
  {
   "for": "the orderability chapter",
   "source": "https://se.eu-cm-kg.ai/book/aio.json"
  },
  {
   "for": "open research",
   "source": "https://www.edisongroup.com/research/reverse-takeover-resets-the-investment-case/BM-3884"
  },
  {
   "for": "the record",
   "source": "https://mcp.se-cm-kg.ai/record/SSME/SE0021181559"
  }
 ],
 "title": "Disruptive Pharma AB (SE0021181559) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}